ANO1 and pulmonary arterial hypertension: Inhibiting TMEM16A function has been proposed as a novel approach to treat several respiratory diseases including asthma, cystic fibrosis, COVID-19 infection and pulmonary arterial hypertension (PAH) (Cabrita et al., 2019; Kunzelmann et al., 2019; Miner et al., 2019; Papp et al., 2019; Singh et al., 2022).